CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.

Carlo MessinaCarlo CattriniGiulia BuzzattiLuigi CerboneElisa ZanardiMarco MessinaFrancesco Boccardo

Published in: Breast cancer research and treatment (2018)

Emerging data provide a new standard treatment for advanced HR+/HER2- breast cancer, regardless of menopausal status, prior hormonal/chemotherapy treatments delivered, sites of metastasis. However, benefits should be balanced with longer treatment duration, toxicities, and costs.

Keyphrases

squamous cell carcinoma
type diabetes
radiation therapy
machine learning
cell cycle
big data
young adults
replacement therapy
artificial intelligence
locally advanced